CETUXIMAB
cetuximab 100 mg/20 mL injection, 20 mL vial
CETUXIMAB (4435K)
4435K
Manner of administration:Injection
Restriction (Streamlined authority code: 4788)
Indication: Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 550 mg | # of repeats: 5 | DPMA: $1,702.38 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Erbitux
(cetuximab 100 mg/20 mL injection, 20 mL vial)
|
||||
| Erbitux
(cetuximab 500 mg/100 mL injection, 100 mL vial)
|
||||